A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Ikena, Senti and others look to clinical presentations at AACR.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
